Bei Wang
Jiangnan University
6 Papers
Bei Wang is an academic researcher from Jiangnan University. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation
Xiaoyun Wang,Yuwei Bai,Bei Wang +2 more
TL;DR: COTL1 is a promising immunotherapeutic and prognostic biomarker across various cancers, including low-grade glioma. Its high expression correlates with decreased survival and is associated with various clinical features, including stemness, immune checkpoints, and tumor mutation burden.
1
A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma
TL;DR: Wang et al. as mentioned in this paper developed a novel prognostic score, the inflammation-based prognosis score (IBPS), to predict the overall survival (OS) of patients with DLBCL.
Naturally Equipped Urinary Exosomes Coated Poly (2−ethyl−2−oxazoline)−Poly (D, L−lactide) Nanocarriers for the Pre−Clinical Translation of Breast Cancer
TL;DR: UEPP−D NPs showed a markedly higher antitumor efficacy and lower side−toxicity in MCF−7 tumor bearing nude mice model, suggesting this versatile nano−system with immune escape, homologous targeting, and rapid response release characteristics could be a promising tool for breast cancer treatment.
Coactosin-Like Protein in Breast Carcinoma: Friend or Foe?
Bei Wang,Limiao Zhao +1 more
TL;DR: COTL 1 expression was higher in breast cancer tissues than in normal tissues, and high COTL1 expression was correlated with poor prognosis and immune cell infiltration, which provides a basis for the development of applications of CotL1 in determining the prognosis of breast cancer and its treatment.
Dendritic cell vaccine for the effective immunotherapy of breast cancer
Jiang Ni,Jinfang Song,Bei Wang,Haiying Hua,Huanhuan Zhu,Xiaoqiang Guo,Shuming Xiong,Yiqing Zhao +7 more
TL;DR: This in-depth study revealed the treatment of MC/Dox/Ce6 was able to elicit TAAs population and DC recruitment, triggering the following immune response cascade, resulting in effective inhibition of both primary and distant growth of breast cancer upon single administration of low dose Dox and Ce6.